To bring scientists, executives and other biopharmaceutical professionals from the Pacific Rim countries together to discuss the latest advances in the biotechnology/pharmaceutical world, the unprecedented challenges and promises facing the industry, and the breathtaking developments and opportunities in Asia/Pacific countries.
-
The BioPacific Conference is the annual flagship event of the CABS. Our mission is to bring scientists,
executives and biopharmaceutical professionals from the Pacific Rim countries together to discuss the
latest advances in the world of life sciences, the unprecedented challenges and promises facing the
industry, and the breathtaking developments and opportunities in Asia/Pacific countries.
BioPacific Conference 2017 (aka 19th Annual Conference of CABS, Chinese- American BioPharmaceutical Society), will be held on June 24th, 2017 in the San Francisco Bay Area at San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA. This full-day event is expected to attract over 500 attendees of life science professionals from the great San Francisco Bay Area.
Date and Time: June 24th, Saturday, 2017, 8:00AM-6:00PM
Location:San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402
The theme of the BioPacific Conference 2017 will be “Leading the New Wave of Life Sciences Innovation– Technology, Policy, and Investment Trends across the Pacific Rim”
- Winners of 2017 CABS K. Fong Award in Life Sciences
- Most promising areas in life sciences including cancer immunotherapy, genomics, and big data analytics
- Success stories of entrepreneurs and emerging companies
- Development of Innovative Therapeutics in China
- IP Considerations in Cross-border Deals between China and US Companies
- US-China Cross-Border Healthcare Investment & Entrepreneurship
- BioPartnering Forum to facilitate interactions including project introduction and talent recruitment between attendees and sponsors
|
2017 CONFERENCE SPEAKERS
|
|
|---|---|
 |
Dr. Yingxiang Wang Co-Founder, President, and CSO Zhejiang Beta Pharmaceuticals |
 |
Dr. Edgar Engleman Managing Partner Vivo Capital |
 |
Dr. Atul Butte Director, Institute for Computational Health Sciences and UCSF Distinguished Professor of Pediatrics University of California, San Francisco |
 |
Dr. Thomas Hudson Vice President, Head of Oncology Discovery and Early Development AbbVie |
 |
Mr. David Flores Founder and CEO BioCentury |
 |
Dr. Xun Xu Director BGI-Research |
 |
Dr. David (Dongliang) Ge President and CEO Apostle, Inc. |
 |
Dr. Hua Tu Chairman and CEO LakePharma |
 |
Dr. Cheni Kwok Managing Partner Linear Dreams |
 |
Dr. Gini Deshpande Founder and CEO NuMedii, Inc. |
 |
Dr. Jie Zhou Partner Morrison & Foerster, LLP |
 |
Dr. Li Feng Partner Finnegan, Henderson, Farabow, Garrett & Dunner, LLP |
 |
Ms. Betty H. Chen Principal Fish & Richardson |
 |
Dr. Cheng Liu Founder & Chief Executive Officer Eureka Therapeutics |
 |
Dr. Baofu (Paul) Ni Vice President Kelun Bo-Tai Biopharmaceutical Co.Ltd |
 |
Dr. Michael (Songzhu) An Founder and CEO Curegenix |
 |
Dr. Wenfeng Xu Associate Director Genentech |
 |
Mr. Wilson Lee Director Sino-Sichuan (Chengdu) Innovation Park Development Co. |
 |
Dr. Wei Zheng Chief Executive Officer Suzhou Connect Biopharmaceuticals, Ltd. |
 |
Dr. Alexis Ji Partner Illumina Ventures |
 |
Dr. Vincent Xiang Partner 6 Dimensions Capital |
 |
Mr. Johnny Sun Co-founder and CIO AccuraGen |
 |
Ms. Lu Zhang Associate Director Ascentage Pharma |
 |
Mr. Zhao Yang President Chengdu Geunion Investment Management Co. Ltd |
